News | February 07, 2024
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company recently received CEP certificate approval for Losartan Potassium by EDQM
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)